Boston Scientific Conference Call Summary Company Overview - **Company**: Boston Scientific - **Analyst**: Robbie Marcus, MedTech Analyst at J.P. Morgan - **Key Executives Present**: Mike Mahoney (CEO), Jon Monson (CFO), Dr. Stein (Chief Medical Officer) Key Industry Insights Market Growth and Product Launches - Boston Scientific is committed to achieving **10%+ growth** over the next three years and **150 basis points of margin improvement** [2] - The company anticipates an increase in the weighted average market growth rate from **8% in 2025 to 9%** over the next three years [2] - The **Pulsed Field Ablation (PFA)** market is projected to grow at a minimum of **15%+** annually, with the overall market growth reaching **20%** in 2025 [4][10] Product Highlights - **Pulsed Field Ablation**: Recognized as a leading product in the medtech market, with significant market share and growth potential [4] - **FARAPOINT**: Recently approved for use in the U.S. and Europe, expected to enhance the portfolio for arrhythmias and expand into non-AF ablations [11][18] - **Watchman**: Holds a **91% market share** in left atrial appendage closure (LAAC), with potential for growth in concomitant procedures [28][30] Competitive Landscape - Boston Scientific's leadership in the PFA market is attributed to strong execution and a comprehensive product pipeline [6] - The company emphasizes the importance of having a complete toolset for electrophysiology (EP) procedures, which includes various catheter types and access solutions [11][19] Financial Performance and Projections Revenue and Market Position - The company is confident in its ability to meet investor day targets and has consistently delivered on commitments [26] - Anticipated growth in the **interventional oncology** and **vascular therapies** divisions, with ongoing trials and product launches expected to drive revenue [40][42] Pricing Strategy - Boston Scientific aims to maintain flat pricing, with expectations of slight declines in certain markets due to competitive pressures [64] - The company has improved its pricing strategy, targeting flat pricing after previously facing headwinds [61] Strategic Initiatives Innovation and R&D - Boston Scientific invests heavily in both internal and external innovation, with a focus on maintaining a strong pipeline and venture portfolio [56][57] - The company is committed to improving operational efficiency, with ongoing initiatives in AI and ERP systems to enhance productivity [62] Market Expansion - The company is optimistic about growth in **China**, projecting sustainable growth in the teens despite market challenges [66] - Boston Scientific is also exploring opportunities in the **ASC (Ambulatory Surgery Center)** market to increase patient volumes and lab capacity [14][15] Additional Insights Clinical Trials and Future Opportunities - The **AVANT GUARD trial** aims to establish catheter ablation as a first-line therapy for persistent atrial fibrillation, with results expected to influence future treatment protocols [21] - The company is exploring the use of its products in various clinical settings, including potential applications for ventricular tachycardia and redo ablations [18][19] Conclusion - Boston Scientific is well-positioned for continued growth with a robust product pipeline, strong market leadership, and a commitment to innovation and operational efficiency. The company is focused on leveraging its competitive advantages in the medtech space to drive future success.

Core Insights - Atrial fibrillation (AF) affects nearly 38 million people globally, with projections indicating this number could nearly triple by 2030. Boston Scientific (BSX) is a leader in left atrial appendage closure (LAAC) devices and is expanding in the pulsed field ablation (PFA) segment, which is the fastest-growing area in AF treatment. The FARAPULSE technology has become widely used since its U.S. launch in 2024 [1][8]. Company Developments - Over 500,000 patients have been treated with the FARAPULSE system, demonstrating consistent real-world results. The one-year results from the FARADISE trial confirm favorable procedural and safety outcomes across various ablation strategies and AF types [2]. - In Q3 2025, FARAPULSE experienced strong double-digit growth in the U.S., driven by the adoption of the OPAL HDx mapping system. One in three FARAPULSE accounts now utilizes the integrated FARAWAVE NAV and OPAL device. The FDA has also approved expanded labeling for the system to treat drug-refractory, symptomatic, persistent AF, supported by clinical evidence from the ADVANTAGE AF trial [3][4]. - Positive results from the second phase of the ADVANTAGE trial support the FARAPOINT PFA catheter as an adjunct technology for treating atrial flutter in patients with persistent AF, with plans for launch by the end of 2025. The company is investing to exceed the expected 15% market growth through 2028 by enhancing its innovative solutions across AF and non-AF segments [4]. Market Position and Performance - Boston Scientific shares have increased by 2.5% over the past year, contrasting with a 3.3% decline in the industry [7]. - The stock is currently trading at a forward five-year Price-to-Earnings (P/E) ratio of 27.06, which is above its median but lower than the industry average [9]. - Earnings estimates for Boston Scientific are trending upward, with current estimates for the current quarter at $0.78 and for the next year at $3.45 [10][11].